We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1726
AZZ Inc
AZZ
$4.58B
| $437K | ﹤0.01% |
10,710
+2,618
| +32% | +$118K |
|
1727
Lands' End
LE
$402M
| $437K | ﹤0.01% |
41,178
-32,701
| -44% | -$429K |
|
|
MODV
1728
DELISTED
ModivCare
MODV
| $437K | ﹤0.01% |
5,168
-409
| -7% | -$41.3K |
|
1729
CNX Resources
CNX
$5.32B
| $434K | ﹤0.01% |
26,340
+7,649
| +41% | +$157K |
|
1730
National Health Investors
NHI
$3.59B
| $434K | ﹤0.01% |
7,157
-1,708
| -19% | -$97.2K |
|
1731
Liberty Energy
LBRT
$3.45B
| $433K | ﹤0.01% |
33,946
+20,477
| +152% | +$321K |
|
1732
Sunrun
RUN
$2.38B
| $433K | ﹤0.01% |
19,707
-8,278
| -30% | -$199K |
|
1733
The Bancorp
TBBK
$2.81B
| $431K | ﹤0.01% |
22,085
-859
| -4% | -$18.4K |
|
1734
Agnico Eagle Mines
AEM
$91.4B
| $429K | ﹤0.01% |
9,374
-330
| -3% | -$18.4K |
|
1735
Intellia Therapeutics
NTLA
$1.68B
| $428K | ﹤0.01% |
8,278
-17,707
| -68% | -$899K |
|
1736
Opko Health
OPK
$1.04B
| $427K | ﹤0.01% |
168,853
-426,126
| -72% | -$1.24M |
|
|
HIBB
1737
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $427K | ﹤0.01% |
9,759
-10,602
| -52% | -$489K |
|
|
NVRO
1738
DELISTED
NEVRO CORP.
NVRO
| $424K | ﹤0.01% |
9,684
-13,691
| -59% | -$753K |
|
1739
Consensus Cloud Solutions
CCSI
$678M
| $422K | ﹤0.01% |
+9,657
| New | +$480K |
|
1740
KRONOS Worldwide
KRO
$977M
| $422K | ﹤0.01% |
22,952
-8,922
| -28% | -$152K |
|
|
CSW
1741
CSW Industrials
CSW
$5.67B
| $421K | ﹤0.01% |
4,082
-1,048
| -20% | -$112K |
|
1742
BlackLine
BL
$1.7B
| $420K | ﹤0.01% |
6,308
-10,663
| -63% | -$730K |
|
1743
Brinker International
EAT
$9.76B
| $420K | ﹤0.01% |
19,085
-7,926
| -29% | -$250K |
|
1744
Integer Holdings
ITGR
$4.25B
| $418K | ﹤0.01% |
5,920
-18,920
| -76% | -$1.45M |
|
|
FRG
1745
DELISTED
Franchise Group, Inc.
FRG
| $417K | ﹤0.01% |
11,896
-8,580
| -42% | -$332K |
|
1746
Generac Holdings
GNRC
$12.2B
| $416K | ﹤0.01% |
2,010
-9,679
| -83% | -$2.38M |
|
1747
The Honest Company
HNST
$561M
| $416K | ﹤0.01% |
+142,315
| New | +$514K |
|
1748
MacroGenics
MGNX
$259M
| $415K | ﹤0.01% |
+140,522
| New | +$739K |
|
1749
Daktronics
DAKT
$1.03B
| $414K | ﹤0.01% |
137,380
-20,722
| -13% | -$69.3K |
|
1750
Forward Air
FWRD
$634M
| $414K | ﹤0.01% |
4,502
-7
| -0.2% | -$649 |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.